Чем лучше осуществить блокаду ренин-ангиотензин-альдостероновой системы

1. Eriksson U, Danilczyk U, Penninger JM. Just the beginning: novel functions for angiotensin-converting enzymes. Curr Biol 2002; 12 (21): R745-52.

2. Ивашкин В.Т., Драпкина О.М. Клиническое значение оксида азота и белков теплового шока. М., 2001.

3. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Ингибиторы ангиотензинпревращающего фермента в лечении сердечно-сосудистых заболеваний (квинаприл и эндотелиальная дисфункция). М.: ООО "Инсайт полиграфик", 2002.

4. Филлипс П.А., Джонстон С.И. Гормоны и почки. Руководство по нефрологии. Под ред. Дж.А.Витворт, Дж.Р.Лоренса. М.: Медицина, 2000; с. 45-58.

5. Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904-12.

6. Jorde UP, Ennezat PV, Lisker J et al. Maximally Recommended Doses of Angiotensin-Converting Enzyme (ACE) Inhibitors Do Not Completely Prevent ACE-Madiated Formation of Angiotensin II in Chronic Heart Failure. Circulation 2000; 101: 844-6.

7. Julius S et al. Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker. The TROPHY study. N Engl J Med 2006; 354: 1685-97.

8. Swedberg K, Pfeffer M, Granger C et al and CHARM-programme investigators. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999; 5: 276-82.

9. Dubrey S. Angiotensin II receptor antagonists in the treatment of heart failure: background to and design of the CHARM study. Brit J Cardiol 2002; 9: 280-6.

10. Pfeffer M, Swedberg K, Granger C et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003; 362: 759-66.

11. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatmen and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563-74.

12. Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875-86.

13. Lacourciere Y, Asmar R. A comparizon of the efficacy and duration of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood presssure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study. Am J Hipertens 1999; 12:1181-7.